Aarti Drugs Limited (AARTIDRUGS.BO)
INR 330.65
(2.85%)
INR 330.65
(2.85%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.71 Billion INR | 3.07% |
| 2022 | 1.66 Billion INR | -18.89% |
| 2021 | 2.05 Billion INR | -26.88% |
| 2020 | 2.8 Billion INR | 98.31% |
| 2019 | 1.41 Billion INR | 57.55% |
| 2018 | 897.51 Million INR | 9.05% |
| 2017 | 823.06 Million INR | 2.16% |
| 2016 | 805.63 Million INR | 17.23% |
| 2015 | 687.24 Million INR | -11.04% |
| 2014 | 772.54 Million INR | 25.18% |
| 2013 | 617.12 Million INR | 36.42% |
| 2012 | 452.38 Million INR | 109.4% |
| 2011 | 216.03 Million INR | -8.9% |
| 2010 | 237.13 Million INR | -16.0% |
| 2009 | 282.3 Million INR | 76.82% |
| 2008 | 159.65 Million INR | 16.22% |
| 2007 | 137.37 Million INR | -0.22% |
| 2006 | 137.67 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 350.1 Million INR | 5.32% |
| 2024 Q1 | 332.4 Million INR | -29.74% |
| 2023 Q4 | 473.1 Million INR | 29.02% |
| 2023 Q2 | 395.9 Million INR | -17.26% |
| 2023 FY | 1.71 Billion INR | 3.07% |
| 2023 Q1 | 478.5 Million INR | -14.69% |
| 2023 Q3 | 366.7 Million INR | -7.38% |
| 2022 FY | 1.66 Billion INR | -18.89% |
| 2022 Q4 | 560.88 Million INR | 52.91% |
| 2022 Q2 | 387.5 Million INR | 11.38% |
| 2022 Q1 | 347.9 Million INR | -37.13% |
| 2022 Q3 | 366.8 Million INR | -5.34% |
| 2021 FY | 2.05 Billion INR | -26.88% |
| 2021 Q4 | 553.38 Million INR | -5.06% |
| 2021 Q3 | 582.9 Million INR | 36.86% |
| 2021 Q1 | 488.1 Million INR | -5.5% |
| 2021 Q2 | 425.9 Million INR | -12.74% |
| 2020 Q4 | 516.53 Million INR | -24.08% |
| 2020 Q1 | 854.5 Million INR | 45.18% |
| 2020 Q2 | 752.7 Million INR | -11.91% |
| 2020 Q3 | 680.4 Million INR | -9.61% |
| 2020 FY | 2.8 Billion INR | 98.31% |
| 2019 Q3 | 277.82 Million INR | -14.01% |
| 2019 Q4 | 588.56 Million INR | 111.84% |
| 2019 FY | 1.41 Billion INR | 57.55% |
| 2019 Q2 | 323.1 Million INR | 43.92% |
| 2019 Q1 | 224.5 Million INR | -18.19% |
| 2018 FY | 897.51 Million INR | 9.05% |
| 2018 Q3 | 208.9 Million INR | 15.73% |
| 2018 Q1 | 233.7 Million INR | -2.58% |
| 2018 Q4 | 274.41 Million INR | 31.36% |
| 2018 Q2 | 180.5 Million INR | -22.76% |
| 2017 FY | 823.06 Million INR | 2.16% |
| 2017 Q4 | 239.9 Million INR | 2.83% |
| 2017 Q3 | 233.3 Million INR | -1.14% |
| 2017 Q2 | 236 Million INR | 107.38% |
| 2017 Q1 | 113.8 Million INR | -45.1% |
| 2016 Q1 | 199.4 Million INR | 7.26% |
| 2016 Q4 | 207.3 Million INR | 16.13% |
| 2016 FY | 805.63 Million INR | 17.23% |
| 2016 Q2 | 220.7 Million INR | 10.68% |
| 2016 Q3 | 178.5 Million INR | -19.12% |
| 2015 Q2 | 157.1 Million INR | -7.86% |
| 2015 Q4 | 185.9 Million INR | 9.16% |
| 2015 Q3 | 170.3 Million INR | 8.4% |
| 2015 Q1 | 170.5 Million INR | -7.91% |
| 2015 FY | 687.24 Million INR | -11.04% |
| 2014 Q2 | 187.5 Million INR | 8.76% |
| 2014 Q4 | 185.14 Million INR | -18.62% |
| 2014 FY | 772.54 Million INR | 25.18% |
| 2014 Q3 | 227.5 Million INR | 21.33% |
| 2014 Q1 | 172.4 Million INR | -21.47% |
| 2013 Q2 | 137.6 Million INR | 16.22% |
| 2013 Q3 | 141.6 Million INR | 2.91% |
| 2013 Q4 | 219.52 Million INR | 55.03% |
| 2013 FY | 617.12 Million INR | 36.42% |
| 2013 Q1 | 118.4 Million INR | -14.26% |
| 2012 FY | 452.38 Million INR | 109.4% |
| 2012 Q1 | 88.8 Million INR | 0.0% |
| 2012 Q2 | 116.2 Million INR | 30.86% |
| 2012 Q3 | 109.4 Million INR | -5.85% |
| 2012 Q4 | 138.08 Million INR | 26.22% |
| 2011 FY | 216.03 Million INR | -8.9% |
| 2010 FY | 237.13 Million INR | -16.0% |
| 2009 FY | 282.3 Million INR | 76.82% |
| 2008 FY | 159.65 Million INR | 16.22% |
| 2007 FY | 137.37 Million INR | -0.22% |
| 2006 FY | 137.67 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 72.164% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 94.598% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 63.597% |
| Granules India Limited | 4.05 Billion INR | 57.707% |
| Indoco Remedies Limited | 984.6 Million INR | -74.099% |
| Achyut Healthcare Limited | 5.73 Million INR | -29805.478% |
| Ajanta Pharma Limited | 8.16 Billion INR | 78.997% |
| Alkem Laboratories Limited | 17.95 Billion INR | 90.454% |
| Alpa Laboratories Limited | 167.76 Million INR | -921.776% |
| Brooks Laboratories Limited | -195.91 Million INR | 974.944% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | -6.135% |
| Bajaj HealthCare Limited | -837.93 Million INR | 304.573% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -127.182% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 96.922% |
| Eris Lifesciences Limited | 3.91 Billion INR | 56.269% |
| FDC Limited | 3.05 Billion INR | 43.838% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 111.415% |
| Gufic Biosciences Limited | 861.35 Million INR | -99.01% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 59.279% |
| Ipca Laboratories Limited | 5.47 Billion INR | 68.682% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -663.114% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 968.891% |
| Lasa Supergenerics Limited | -217.3 Million INR | 888.833% |
| Laurus Labs Limited | 1.6 Billion INR | -6.769% |
| Lupin Limited | 19.14 Billion INR | 91.046% |
| Mankind Pharma Limited | 19.12 Billion INR | 91.039% |
| Medicamen Biotech Limited | 109.31 Million INR | -1468.184% |
| Medico Remedies Limited | 82.9 Million INR | -1967.546% |
| Megasoft Limited | -127.46 Million INR | 1444.815% |
| NATCO Pharma Limited | 13.88 Billion INR | 87.653% |
| Piramal Pharma Limited | 178.2 Million INR | -861.943% |
| RPG Life Sciences Limited | 876.6 Million INR | -95.549% |
| Sigachi Industries Limited | 571.8 Million INR | -199.786% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 98.21% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 42.914% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -577.162% |
| Unichem Laboratories Limited | -704.74 Million INR | 343.235% |
| Wanbury Limited | 559.56 Million INR | -206.343% |
| Windlas Biotech Limited | 581.87 Million INR | -194.599% |
| ZIM Laboratories Limited | 172.46 Million INR | -893.936% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 95.559% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 144.27% |
| Divi's Laboratories Limited | 16 Billion INR | 89.286% |
| Hester Biosciences Limited | 188.89 Million INR | -807.503% |
| Procter & Gamble Health Limited | 2 Billion INR | 14.709% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -281.161% |
| Bal Pharma Limited | 73.92 Million INR | -2218.906% |
| Strides Pharma Science Limited | -706.14 Million INR | 342.754% |
| Venus Remedies Limited | 284.9 Million INR | -501.662% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 20.97% |
| Nectar Lifesciences Limited | 49.95 Million INR | -3331.796% |
| Shilpa Medicare Limited | 318.74 Million INR | -437.796% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | -27.515% |
| Suven Life Sciences Limited | -1.05 Billion INR | 263.137% |
| Ind-Swift Limited | 142.31 Million INR | -1104.515% |
| Valiant Laboratories Limited | 3.19 Million INR | -53535.232% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 68.981% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 130.212% |
| Themis Medicare Limited | 435.23 Million INR | -293.849% |
| Hikal Limited | 696.02 Million INR | -146.283% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 89.651% |
| Sequent Scientific Limited | -358.69 Million INR | 577.901% |
| Novartis India Limited | 851.9 Million INR | -101.219% |
| Wockhardt Limited | -4.63 Billion INR | 137.023% |
| Jubilant Pharmova Limited | 771 Million INR | -122.332% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -24070.643% |
| Neuland Laboratories Limited | 3 Billion INR | 42.876% |
| Morepen Laboratories Limited | 961.59 Million INR | -78.264% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -1073.985% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 1989.593% |